Grail is conducting trials with the NHS, seeking FDA approval for its Galleri test, and presenting data at ASCO.
5 reports, 3 independent
Updated Sep 23
No new developments lately
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Grail is conducting trials with the NHS, seeking FDA approval for its Galleri test, and presenting data at ASCO.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA committee voted on Grail's premarket approval.1 source
S&P Global reported on Grail's stock performance as the company continues NHS trials and seeks FDA approval.1 source
Grail advances its Galleri test through NHS trials, FDA approval seeks, and ASCO presentation.1 source
Keep exploring
The entities involved
Related events
- The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.
- A study conducted at Mayo Clinic on September 24 validated the efficacy of Grail's multi-cancer early detection test.
- GRAIL utilizes a central laboratory in North Carolina and leverages Quest locations for blood sample collection for its multi-cancer early detection test.
- A key meeting was held to review the Galleri blood test developed by GRAIL.